Servatus Biopharmaceuticals Ltd

22/08/2023

28/06/2023

A great story from Jessica Ross at the ABC News (Australian Broadcasting Corporation) sharing the exciting news that our live biotherapeutic treatment for insomnia has shown promising results in the first stage of its Phase 1/2 human clinical trials.

Jessica talked to Servatus Ltd CEO Dr Wayne Finlayson about the trial so far, and the potential of live biotherapeutics to treat insomnia and other conditions.

The trial, which is being conducted by Dr Deanne Curtin at the Sleep Disorders Centre at The Prince Charles Hospital in Brisbane, is set to expand to further verify the results seen so far.

More than half the country experiences disrupted sleep, but an Australian-first clinical trial of a bacteria-based treatment for insomnia is delivered "very promising" results.

28/06/2023

https://www.abc.net.au/news/2023-06-28/scientists-trial-gut-bacteria-treatment-for-insomnia/102536268 To register your interest in this trial please visit myclinicalstudy.com.au

Trusted and independent source of local, national and world news. In-depth analysis, business, sport, weather and more.

28/06/2023

https://www.abc.net.au/news/2023-06-28/gut-microbiome-servatus-insomnia-treatment-clinical-trials/102504174?utm_campaign=abc_news_web&utm_content=link&utm_medium=content_shared&utm_source=abc_news_web

To register your interest in this trial please visit https://myclinicalstudy.com.au/

More than half the country experiences disrupted sleep, but an Australian-first clinical trial of a bacteria-based treatment for insomnia is delivered "very promising" results.

27/06/2023

Today marks , which recognises the importance of microbes in the health of all of us.

At Servatus Biopharmaceuticals Ltd, the microbiome is central to the work we’re doing to develop live biotherapeutic treatments, including for Irritable Bowel Syndrome with constipation (IBSc), insomnia, rheumatoid arthritis, and other diseases and conditions.

01/06/2023

https://fb.me/2eHkDK78OyWaKMo

22/05/2023

We are excited to share that Phase I clinical trials our live biotherapeutic treatment for Irritable Bowel Syndrome with constipation (IBSc) have shown extremely encouraging results.

Servatus partnered with leading Gerald Holtmann at Princess Alexandra Hospital, Brisbane to conduct the trial, with results validating both safety and clinically meaningful improvements by reducing constipation symptoms in 48% of participants and improving quality of life in 62% of participants.

Learn more here: https://servatus.com.au/news/

11/05/2023

We are pleased to announce that our Head of Clinical Research, Dr Samantha Coulson and Research Scientist Dr Renato Lemgruber are presenting at next week’s Microbiome Connect: Asia conference in Seoul, South Korea.

Dr Coulson and Dr Lemgruber will be speaking on key and topics.

Microbiome Connect: Asia is a forum dedicated to accelerating pipeline development in the region by showcasing updates from leading companies, addressing regional regulatory issues, and promoting collaboration between industry, academia, and service providers.

Follow the link to learn more: https://www.microbiomeconnectasia.com/events/microbiome-connect-asia-2023.

22/03/2023

Another great story about our rheumatoid arthritis clinical trial was recently featured on ABC TV + iview across the country.

The story includes interviews with Servatus CEO Dr Wayne Finlayson and principal investigator Professor Peter Nash, who both discuss the world-first based clinical trial.

In a world first trial, Queensland scientists investigate whether introducing live, beneficial bacteria to the gut could treat or even cure rheumatoid arthri...

15/03/2023

https://www.abc.net.au/news/2023-03-16/world-first-clinical-trial-gut-microbiome-rheumatoid-athritis/102046546?utm_campaign=abc_news_web&utm_content=link&utm_medium=content_shared&utm_source=abc_news_web

Scientists investigate whether introducing live, beneficial bacteria to the gut could treat or even cure the disease in a world-first trial.

24/01/2023

New Rheumatoid arthritis (RA) Clinical Trial

Who can take part in this study?

In order to be eligible to participate in the study, you must meet all of the following:
● You are aged 18 - 80 years old
● You have been diagnosed with Rheumatoid arthritis

Who is unable to take part in this study?

Unfortunately, if you meet any of the following, this study is not the right fit for you:
● Anyone who has a history of any other rheumatic autoimmune disease, other than Sjogren’s syndrome

How long will the study take?

If you agree to take part, and the study is suitable for you, your participation in the study is expected to last up to 16 weeks. This includes:
● 12 week treatment period
● 4 week follow-up period
● 5 study visits and 1 phone call

To register: https://www.surveymonkey.com/r/RheumatoidArthritisTrial